Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Section 4 of 6

Clinical evidence

380 evidence topics · 46 sources

Study summaries

SynAIRgy

Objective
Location and study date
Registry study dates
FieldQuoted record
Study start (actual)“2023-09-16”
Primary completion (actual)“2025-03-10”
Study completion (actual)“2025-03-14”
Enrollment (actual)“646”
Registry results posting dates
FieldQuoted record
Results first submitted“2026-08-18”
Results first posted“2026-09-11”
Study design
Eligibility criteria
Inclusion and exclusion criteria in the publication

“Patients aged ≥18 years with mild-to-severe OSA who had failed or refused PAP therapy were screened for eligibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants with AHI ≥5 events/hour were initially enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“An apnea was defined by an event with ≥90% reduction in airflow for ≥10 seconds and hypopnea by ≥30% reduction in airflow for ≥10 seconds associated with a ≥4% decrease in the oxygen saturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The eligibility criterion of enrolling participants with AHI ≥5 events/hour was subsequently changed to ≥10 to ≤45 events/hour to avoid overrepresentation of participants with very severe or very mild OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Other inclusion criteria were an 8-item Patient-Reported Outcomes Measurement Information System (PROMIS)–Fatigue T-score >50, representing above-average fatigue and a body mass index (BMI) of 18.5 to 40 kg/m2 in men or 18.5 to 42 kg/m2 in women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Key exclusion criteria were clinically significant or medically uncontrolled cardiovascular disease, presence of narcolepsy, restless leg syndrome requiring medication, rapid eye movement (REM) sleep behavior disorder, bothersome symptoms of insomnia, and craniofacial malformation syndromes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Additional exclusion criteria in the design paper

“Clinically significant or medically uncontrolled cardiovascular disease, or resting heart rate >100), untreated or unstable coronary artery disease, heart failure, cerebrovascular event or revascularization within 3 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Schizophrenia, schizoaffective disorder, generalized anxiety disorder or bipolar disorder according to DSM-5 criteria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Attempted suicide within 1 year prior to screening, or current suicidal ideation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Blood pressure >145/90 mmHg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Narrow angle glaucoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Women who are pregnant or nursing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Treatment
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Treatment policy estimand (intent-to-treat) and on-treatment estimand

“Primary analyses of the efficacy endpoints were performed using an intent-to-treat approach (ITT); supportive analyses were performed using the on-treatment estimand.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ITT analysis included all randomized participants who received ≥1 dose of AD109/placebo and evaluated endpoints regardless of treatment adherence or discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the ITT estimand, missing data were assumed to be missing-not-at-random, and endpoints were analyzed with a pattern-mixture model using a jump-to-reference approach by means of sequential modeling with multiple imputation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The on-treatment estimand included all randomized participants who received ≥1 dose of AD109/placebo and who had ≥1 post-baseline PSG assessment on treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The on-treatment estimand focused on endpoints observed during active treatment exposure and excluded data collected after treatment discontinuation, with missing values imputed using a last observation carried forward approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Results
Participant disposition
Registry participant flow and reasons for study withdrawal
Milestone or reasonAD109Placebo
Started“324”“322”
Completed“269”“276”
Not completed“55”“46”
Adverse event“4”“1”
Lost to follow-up“15”“15”
Physician decision“2”“2”
Site terminated by sponsor“8”“2”
Withdrawal by subject“21”“22”
Other or not reported“5”“4”
Baseline characteristics
Baseline characteristics, intent-to-treat set, AHI with 4% desaturation hypopnea rule
CharacteristicAD109PlaceboTotal
Participants“AD109 (n = 302)”View highlighted excerpt for this quote“Placebo (n = 313)”View highlighted excerpt for this quote“Total (N = 615)”View highlighted excerpt for this quote
Age, years, median (minimum-maximum)“59 (24-83)”View highlighted excerpt for this quote“58 (25-87)”View highlighted excerpt for this quote“58 (24-87)”View highlighted excerpt for this quote
Female, n (%)“150 (49.7)”View highlighted excerpt for this quote“153 (48.9)”View highlighted excerpt for this quote“303 (49.3)”View highlighted excerpt for this quote
Black or African American, n (%)“55 (18.2)”View highlighted excerpt for this quote“62 (19.8)”View highlighted excerpt for this quote“117 (19.0)”View highlighted excerpt for this quote
White, n (%)“212 (70.2)”View highlighted excerpt for this quote“216 (69.0)”View highlighted excerpt for this quote“428 (69.6)”View highlighted excerpt for this quote
Asian, n (%)“23 (7.6)”View highlighted excerpt for this quote“22 (7.0)”View highlighted excerpt for this quote“45 (7.3)”View highlighted excerpt for this quote
Hispanic or Latino, n (%)“63 (20.9)”View highlighted excerpt for this quote“69 (22.0)”View highlighted excerpt for this quote“132 (21.5)”View highlighted excerpt for this quote
Body weight, kg, mean (SD)“93.3 (17.0)”View highlighted excerpt for this quote“93.1 (17.1)”View highlighted excerpt for this quote“93.2 (17.0)”View highlighted excerpt for this quote
BMI, kg/m2, median (minimum-maximum)“32.5 (18.5-41.9)”View highlighted excerpt for this quote“32.4 (20.1-42.0)”View highlighted excerpt for this quote“32.4 (18.5-42.0)”View highlighted excerpt for this quote
BMI 18.5-29.9 kg/m2, n (%)“107 (35.4)”View highlighted excerpt for this quote“102 (32.6)”View highlighted excerpt for this quote“209 (34.0)”View highlighted excerpt for this quote
BMI 30-34.9 kg/m2, n (%)“100 (33.1)”View highlighted excerpt for this quote“111 (35.5)”View highlighted excerpt for this quote“211 (34.3)”View highlighted excerpt for this quote
BMI 35 kg/m2 or higher, n (%)“95 (31.5)”View highlighted excerpt for this quote“100 (31.9)”View highlighted excerpt for this quote“195 (31.7)”View highlighted excerpt for this quote
AHI, events/h, median (minimum-maximum)“19.8 (5.2-101.8)”View highlighted excerpt for this quote“19.1 (5.1-70.0)”View highlighted excerpt for this quote“19.6 (5.1-101.8)”View highlighted excerpt for this quote
Mild OSA, AHI 5 to <15, n (%)“105 (34.8)”View highlighted excerpt for this quote“109 (34.8)”View highlighted excerpt for this quote“214 (34.8)”View highlighted excerpt for this quote
Moderate OSA, AHI 15 to <30, n (%)“125 (41.4)”View highlighted excerpt for this quote“134 (42.8)”View highlighted excerpt for this quote“259 (42.1)”View highlighted excerpt for this quote
Severe OSA, AHI 30 or higher, n (%)“72 (23.8)”View highlighted excerpt for this quote“70 (22.4)”View highlighted excerpt for this quote“142 (23.1)”View highlighted excerpt for this quote
ODI, events/h, median (minimum-maximum)“27.3 (6.8-96.3)”View highlighted excerpt for this quote“26.9 (4.5-79.3)”View highlighted excerpt for this quote“27.0 (4.5-96.3)”View highlighted excerpt for this quote
HB, %min/h, median (minimum-maximum)“33.7 (0.8-379.8)”View highlighted excerpt for this quote“28.8 (2.4-272.8)”View highlighted excerpt for this quote“31.1 (0.8-379.8)”View highlighted excerpt for this quote
PROMIS-Fatigue T-score, mean (SD)“59.2 (7.0)”View highlighted excerpt for this quote“58.9 (6.7)”View highlighted excerpt for this quote“59.0 (6.8)”View highlighted excerpt for this quote
PROMIS-Sleep Impairment T-score, mean (SD) [n]“58.9 (7.2) [299]”View highlighted excerpt for this quote“58.6 (7.4) [309]”View highlighted excerpt for this quote“58.7 (7.3) [608]”View highlighted excerpt for this quote
ESS score, mean (SD) [n]“10.0 (4.6) [299]”View highlighted excerpt for this quote“10.1 (4.7) [311]”View highlighted excerpt for this quote“10.0 (4.6) [610]”View highlighted excerpt for this quote
PAP intolerance, n (%)“208 (68.9)”View highlighted excerpt for this quote“203 (64.9)”View highlighted excerpt for this quote“411 (66.8)”View highlighted excerpt for this quote
PAP refusal, n (%)“94 (31.1)”View highlighted excerpt for this quote“111 (35.5)”View highlighted excerpt for this quote“205 (33.3)”View highlighted excerpt for this quote
Hypertension, n (%)“152 (50.3)”View highlighted excerpt for this quote“153 (48.9)”View highlighted excerpt for this quote“305 (49.6)”View highlighted excerpt for this quote
Diabetes, n (%)“52 (17.2)”View highlighted excerpt for this quote“51 (16.3)”View highlighted excerpt for this quote“103 (16.7)”View highlighted excerpt for this quote
Mood disturbances, n (%)“60 (19.9)”View highlighted excerpt for this quote“45 (14.4)”View highlighted excerpt for this quote“105 (17.1)”View highlighted excerpt for this quote
Insomnia, n (%)“17 (5.6)”View highlighted excerpt for this quote“15 (4.8)”View highlighted excerpt for this quote“32 (5.2)”View highlighted excerpt for this quote
Registry baseline age and mean AHI with 4% desaturation hypopnea rule, Primary Full Analysis Set
CharacteristicAD109PlaceboTotal
Age, years, mean (SD)“57.5(10.67)”“57.1(11.11)”“57.3(10.89)”
Baseline AHI4, events/hr, mean (SD)“22.13(11.819)”“21.47(10.607)”“21.79(11.214)”
Baseline oxygenation measures, all 646 randomized participants
Efficacy results
Primary and key secondary endpoints at week 26, treatment policy estimand, AHI with 4% desaturation hypopnea rule
EndpointAD109PlaceboDifference95% CIP value
Change in AHI, LS mean (95% CI), events/h (primary)“−3.3 (−5.1 to −1.5)”View highlighted excerpt for this quote“0.7 (−1.0 to 2.4)”View highlighted excerpt for this quote“−4.0”View highlighted excerpt for this quote“(−6.4 to −1.6)”View highlighted excerpt for this quote“P = .001”View highlighted excerpt for this quote
Change in ODI, LS mean (95% CI), events/h“−3.7 (−5.6 to −1.7)”View highlighted excerpt for this quote“0.9 (−1.1 to 2.8)”View highlighted excerpt for this quote“−4.5”View highlighted excerpt for this quote“(−7.3 to −1.8)”View highlighted excerpt for this quote“P = .001”View highlighted excerpt for this quote
Change in PROMIS-Fatigue T-score, LS mean (95% CI)“−7.4 (−8.3 to −6.5)”View highlighted excerpt for this quote“−6.2 (−7.1 to −5.3)”View highlighted excerpt for this quote“−1.2”View highlighted excerpt for this quote“(−2.4 to 0.0)”View highlighted excerpt for this quote“P = .059”View highlighted excerpt for this quote
Percent reduction in geometric mean HB, LS mean (95% CI)“44.7 (34.5-53.4)”View highlighted excerpt for this quote“8.5 (‒8.1 to 22.5)”View highlighted excerpt for this quote“39.6”View highlighted excerpt for this quote“(23.6-52.3)”View highlighted excerpt for this quote“P <.0001”View highlighted excerpt for this quote
Change in PROMIS-Sleep Impairment T-score, LS mean (95% CI)“−7.6 (−8.5 to −6.6)”View highlighted excerpt for this quote“−6.9 (−7.8 to −5.9)”View highlighted excerpt for this quote“−0.7”View highlighted excerpt for this quote“(−2.0 to 0.7)”View highlighted excerpt for this quote“P = .316”View highlighted excerpt for this quote
Participants with ≥50% reduction in AHI, n (%)“78 (25.8)”View highlighted excerpt for this quote“62 (19.8)”View highlighted excerpt for this quote“5.7”View highlighted excerpt for this quote“(−1.0 to 12.4)”View highlighted excerpt for this quote“P = .182”View highlighted excerpt for this quote
Primary and key secondary endpoints at week 26, on-treatment estimand, AHI with 4% desaturation hypopnea rule
EndpointAD109PlaceboDifference95% CIP value
Change in AHI, LS mean (95% CI), events/h (primary)“−6.1 (−7.8 to −4.4)”View highlighted excerpt for this quote“0.4 (−1.2 to 2.0)”View highlighted excerpt for this quote“−6.5”View highlighted excerpt for this quote“(−8.8 to −4.3)”View highlighted excerpt for this quote“P <.0001”View highlighted excerpt for this quote
Change in ODI, LS mean (95% CI), events/h“−6.5 (−8.4 to −4.6)”View highlighted excerpt for this quote“0.7 (−1.1 to 2.5)”View highlighted excerpt for this quote“−7.2”View highlighted excerpt for this quote“(−9.8 to −4.7)”View highlighted excerpt for this quote“P <.0001”View highlighted excerpt for this quote
Change in PROMIS-Fatigue T-score, LS mean (95% CI)“−7.5 (−8.4 to −6.6)”View highlighted excerpt for this quote“−6.2 (−7.0 to −5.3)”View highlighted excerpt for this quote“−1.4”View highlighted excerpt for this quote“(−2.6 to −0.1)”View highlighted excerpt for this quote“P = .030”View highlighted excerpt for this quote
Percent reduction in geometric mean HB, LS mean (95% CI)“60.5 (52.8-66.9)”View highlighted excerpt for this quote“14.7 (‒0.7 to 27.8)”View highlighted excerpt for this quote“53.6”View highlighted excerpt for this quote“(41.0-63.6)”View highlighted excerpt for this quote“P <.0001”View highlighted excerpt for this quote
Change in PROMIS-Sleep Impairment T-score, LS mean (95% CI)“−7.6 (−8.6 to −6.7)”View highlighted excerpt for this quote“−6.8 (−7.7 to −5.9)”View highlighted excerpt for this quote“−0.8”View highlighted excerpt for this quote“(−2.2 to 0.5)”View highlighted excerpt for this quote“P = .231”View highlighted excerpt for this quote
Participants with ≥50% reduction in AHI, n (%)“103 (39.6)”View highlighted excerpt for this quote“66 (22.3)”View highlighted excerpt for this quote“17.3”View highlighted excerpt for this quote“(9.6-25.0)”View highlighted excerpt for this quote“P <.0001”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Epworth Sleepiness Scale and patient global impression endpoints

No evidence found.

Safety results
Overall safety summary, safety analysis set
EventAD109 (n = 325), n (%)Placebo (n = 319), n (%)
Any TEAE“230 (70.8)”View highlighted excerpt for this quote“149 (46.7)”View highlighted excerpt for this quote
Any treatment-related TEAE“190 (58.5)”View highlighted excerpt for this quote“75 (23.5)”View highlighted excerpt for this quote
Any severe TEAE“15 (4.6)”View highlighted excerpt for this quote“10 (3.1)”View highlighted excerpt for this quote
Any serious TEAE“5 (1.5)”View highlighted excerpt for this quote“8 (2.5)”View highlighted excerpt for this quote
Any TEAE leading to treatment discontinuation“69 (21.2)”View highlighted excerpt for this quote“10 (3.1)”View highlighted excerpt for this quote
Dry mouth“115 (35.4)”View highlighted excerpt for this quote“29 (9.1)”View highlighted excerpt for this quote
Insomnia (initial, middle, or unspecified)“67 (20.6)”View highlighted excerpt for this quote“15 (4.7)”View highlighted excerpt for this quote
Nausea“37 (11.4)”View highlighted excerpt for this quote“2 (0.6)”View highlighted excerpt for this quote
Urinary hesitation“29 (8.9)”View highlighted excerpt for this quote“1 (0.3)”View highlighted excerpt for this quote
Constipation“17 (5.2)”View highlighted excerpt for this quote“4 (1.3)”View highlighted excerpt for this quote
Somnolence“17 (5.2)”View highlighted excerpt for this quote“10 (3.1)”View highlighted excerpt for this quote
Registry adverse events at the 5% reporting threshold, safety population
EventAD109, affected/at risk (%)Placebo, affected/at risk (%)
Serious adverse events, total“5/325 (1.54%)”“8/319 (2.51%)”
Other adverse events, total“176/325 (54.15%)”“50/319 (15.67%)”
Dry mouth“115/325 (35.38%)”“29/319 (9.09%)”
Nausea“37/325 (11.38%)”“2/319 (0.63%)”
Constipation“17/325 (5.23%)”“4/319 (1.25%)”
Somnolence“17/325 (5.23%)”“10/319 (3.13%)”
Middle insomnia“38/325 (11.69%)”“10/319 (3.13%)”
Initial insomnia“30/325 (9.23%)”“4/319 (1.25%)”
Urinary hesitation“29/325 (8.92%)”“1/319 (0.31%)”
Heart rate and blood pressure, safety analysis set
Study limitations
Summary
  • Design: 26 weeks of treatment against placebo, with polysomnography at baseline and weeks 4 and 26; no active comparator. Dose reduction was not permitted, and participants could start PAP during the trial.
  • Population: adults intolerant of or refusing PAP, with a PROMIS-Fatigue T-score above 50 and a BMI cap of 40 (men) or 42 (women) kg/m2. Exclusions included clinically significant cardiovascular disease, blood pressure above 145/90 mmHg, bothersome insomnia, specified psychiatric disorders, and narrow angle glaucoma. Sites were limited to the United States and Canada, which the authors state may not represent OSA in other geographies.
  • Eligibility AHI changed during enrollment: protocol version 2.0 (July 2023) required more than 5 to 45 events/h, version 5.0 (February 2024) required 10 to 45, and the publication states participants with AHI of 5 or more were enrolled first. The 2024 congress abstract described AHI4 of 5 or more, and the 2025 abstract AHI4 above 5 with no upper limit. Enrollment ran from December 20, 2023 to March 26, 2025.
  • Severity mix: enrollment limits capped each AHI4 stratum at about 20% to 40%, and the authors state the population skewed toward mild-to-moderate disease, which can limit absolute effects; the editorial gives a median baseline AHI of 19.6.
  • Endpoint change: protocol version 4.0 (December 2023) named the proportion with at least 50% AHI reduction as the primary endpoint. Amendment 6.0 (17 April 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”. The registry version of 2025-03-18 named the proportion of participants with reduction in AHI as the primary outcome, and the next version, submitted 2025-11-18, changed the outcome measures. The amendment postdates the registry's actual primary completion date (2025-03-10). Statistical analysis plan version 2.0 (22 April 2025) added the relative change in AHI on the log scale as an exploratory analysis.
  • Estimands and missing data: the primary treatment policy analysis assumed data missing not at random (jump-to-reference multiple imputation). The supportive on-treatment estimand excluded data collected after treatment discontinuation and imputed missing values by last observation carried forward; it included 260 participants on AD109 and 296 on placebo, against 302 and 313 in the treatment policy set. The topline release reported the on-treatment relative reduction (55.6%) beside the treatment policy primary result (p=0.001).
  • Analysis-set exclusions: 22 participants (16 AD109, 6 placebo) at site 1416, terminated for Good Clinical Practice noncompliance, and 7 participants in the exploratory GLP-1 receptor agonist cohort were excluded from efficacy analyses; that cohort's analyses were not reported because of low enrollment.
  • Discontinuation: treatment discontinuation before 26 weeks was 34.3% with AD109 and 16.3% with placebo in the publication, which the authors state likely diminished the observed benefit; the prospectus reports 34.6% and 16.5% at month 6 in the main cohort. Treatment discontinuation due to adverse events was 21.2% and 3.1%; study withdrawal due to adverse events in the registry was 4 and 1 participants.
  • Hierarchical testing: under the treatment policy estimand, PROMIS-Fatigue (P = .059) did not reach significance, so formal testing ended before hypoxic burden, and the responder endpoint was not significant (P = .182).
  • Patient-reported outcomes: the authors cite a placebo response in both arms and possible expectation bias, and state insomnia was not assessed in a standardized manner although the PAP-intolerant population may have been enriched for subclinical insomnia.
  • Clinical meaningfulness: at the pre-NDA meeting the FDA gave feedback on the clinical meaningfulness of the primary endpoint results and the limitations of the PROs, and indicated additional analyses and justification may be needed. The editorial states the clinical significance of the placebo-adjusted reduction of about 4 events per hour is uncertain as a continuous measure, and that durability, long-term safety, and effects on cardiovascular events require further study.
  • Sponsor: the prospectus describes SynAIRgy as a trial the company conducted.

LunAIRo

Objective
Location and study date
Study design
Eligibility criteria
Key exclusion criteria and fatigue threshold in the design paper

“Current bothersome symptoms of insomnia (difficulty initiating or maintaining sleep, as distinct from unrefreshing sleep or other symptoms attributable to OSA). Participants treated with insomnia can be enrolled if symptoms are controlled” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Schizophrenia, schizoaffective disorder, generalized anxiety disorder or bipolar disorder according to DSM-5 criteria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Attempted suicide within 1 year prior to screening, or current suicidal ideation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Blood pressure >145/90 mmHg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Narrow angle glaucoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Only participants who refuse or are intolerant to PAP and with a raw PROMIS-Fatigue score ≥17 (fatigue level above average of the population; a raw score of 17 is equivalent to a T-score of 50.4) are eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Treatment
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Primary endpoint: proportion with at least 50% reduction in AHI4 at six months in the baseline abstract, May 2025, superseded in June 2025
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Participant flow in the ClinicalTrials.gov record
Milestone or reasonAD109Placebo
Started“329”“331”
Completed“250”“274”
Not completed“79”“57”
Adverse Event“12”“7”
Lost to Follow-up“24”“20”
Other/Not Reported“5”“2”
Physician Decision“2”“7”
Site Terminated by Sponsor“3”“2”
Withdrawal by Subject“33”“19”
Baseline characteristics
Baseline characteristics of the full analysis set in the ClinicalTrials.gov record
CharacteristicAD109 (n = 324)Placebo (n = 326)
Age, years, mean (SD)“57.2(10.26)”“57.4(10.72)”
Female“160”“138”
Male“164”“188”
Black or African American“58”“53”
White“238”“246”
Baseline AHI4 below 15“119”“125”
Baseline AHI4 15 to 30“109”“104”
Baseline AHI4 above 30“96”“97”
Baseline AHI4, events/hr, mean (SD)“24.03(16.692)”“24.69(18.735)”
Efficacy results
Week 26 change from baseline in AHI4, treatment policy and while-on-treatment estimands, in the ClinicalTrials.gov record
Estimand and armLS mean change, events/hrLower 95% CIUpper 95% CI
Treatment policy, AD109 (n = 324)“-3.88”“-5.37”“-2.39”
Treatment policy, placebo (n = 326)“0.21”“-1.24”“1.65”
While-on-treatment, AD109 (n = 240)“-5.83”“-7.51”“-4.15”
While-on-treatment, placebo (n = 293)“-0.02”“-1.55”“1.50”
Pooled phase 3 analysis: week 26 AHI adjusted for changes in REM sleep and BMI, on-treatment estimand
Model, LS mean (95% CI), events/h at week 26AD109 (n = 500)Placebo (n = 589)Estimated treatment difference (95% CI)p-value
Primary model for change from baseline in AHI“–6.1 (–7.3 to –4.9)”“0.1 (–1.0 to 1.2)”“–6.2 (–7.8 to –4.6)”“<0.0001”
Model adjusted for change in proportion of REM sleep“–5.7 (–7.1 to –4.2)”“0.2 (–1.1 to 1.4)”“–5.9 (–7.9 to –3.8)”“<0.0001”
Model adjusted for change in BMI“–5.1 (–6.4 to -3.8)”“–0.2 (–1.4 to 0.9)”“–4.9 (–6.6 to –3.1)”“<0.0001”
Health-related quality of life and patient-reported outcomes
Safety results
Non-serious adverse events in at least 5% of participants in either arm
Serious adverse events and deaths
EventAD109, affected / at risk (%)Placebo, affected / at risk (%)
All-cause mortality“0/328 (0.00%)”“0/327 (0.00%)”
Any serious adverse event“5/328 (1.52%)”“10/327 (3.06%)”
Acute myocardial infarction“0/328 (0.00%)”“1/327 (0.31%)”
Aortic dissection“1/328 (0.30%)”“0/327 (0.00%)”
Intracranial aneurysm“1/328 (0.30%)”“0/327 (0.00%)”
Ischaemic stroke“0/328 (0.00%)”“1/327 (0.31%)”
Suicide attempt“0/328 (0.00%)”“1/327 (0.31%)”
Pooled phase 3 analysis: heart rate and blood pressure, safety analysis set
MeasureAD109 (n = 653)Placebo (n = 646)p-value
Heart rate, beats/min, mean change (SD) to week 26, evening pre-PSG“2.0 (11.2)”“-0.7 (10.0)”Not reported
Heart rate, beats/min, mean change (SD) to week 26, morning post-PSG“3.4 (9.5)”“-0.7 (9.4)”Not reported
Heart rate ≥100 beats/min on study, n (%)“48 (7.4)”“28 (4.3)”“0.021”
Systolic blood pressure ≥140 mm Hg on study, n (%)“175 (26.8)”“168 (26.0)”“0.760”
Diastolic blood pressure ≥90 mm Hg on study, n (%)“146 (22.4)”“131 (20.3)”“0.368”
Study limitations
Summary
  • Publication status: results are available from a congress abstract, the registry results (first posted 2026-11-03), company releases, and the prospectus; the 2026 editorial on SynAIRgy described LunAIRo results as forthcoming.
  • Design: placebo-controlled for 51 weeks, with the primary endpoint at week 26; week 51 efficacy was analyzed as a tertiary endpoint. No active comparator was used, dose reduction was not permitted, and all 64 sites were in the United States.
  • Population: adults intolerant of or refusing PAP with a PROMIS-Fatigue raw score of at least 17, and a BMI cap of 40 (men) or 42 (women) kg/m2. Exclusions included bothersome insomnia, clinically significant cardiac disease, blood pressure above 145/90 mmHg, specified psychiatric disorders, and narrow angle glaucoma.
  • Eligibility AHI differs by source: protocol version 4.0 states AHI4 of more than 5 and up to 45, the registry states AHI of more than 5, and the baseline abstract states no upper limit. The design paper states caps could be added during the trial.
  • Severity mix: in the pooled phase 3 population, 51% had AHI below 20 events/h and 74% below 30, per the prospectus.
  • Endpoint change: the 2025 baseline abstract named the proportion with at least 50% AHI4 reduction at six months as the primary endpoint. Protocol amendment 4.0 (June 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”, after the registry's actual primary completion date (2025-05-07).
  • Estimands and missing data: the treatment policy estimand assumed data missing not at random with control-based imputation. The on-treatment estimand excluded data after treatment discontinuation with last observation carried forward and included 240 participants on AD109 and 293 on placebo, against 324 and 326 in the full analysis set. The company states the on-treatment estimand gave the most clinically relevant estimate, and attributes the smaller week 51 response to higher discontinuation with AD109 and control-based imputation. The topline release reported the on-treatment relative reduction (46.8%).
  • Analysis-set exclusions: participants at site 1308 were excluded from the full analysis set after the site was terminated.
  • Discontinuation: treatment discontinuation due to adverse events was 23.7% with AD109 and 6.6% with placebo by month 6 and 28.6% and 10.0% by month 12; overall treatment discontinuation at month 12 was 46.5% and 25.1% (prospectus, main cohort). In the registry, 250 of 329 participants on AD109 and 274 of 331 on placebo completed the study.
  • Patient-reported outcomes: AD109 did not significantly reduce the PROMIS-Fatigue T-score under either estimand, and no treatment effect was observed on PROMIS Sleep Impairment.
  • Pooled analyses: Patel et al. (2026a) reports the pooled 39.0% versus 18.8% responder result without an estimand label, while the prospectus labels the pooled 39% as on treatment. The prospectus states the phase 3 trials were not designed or powered to assess cardiovascular outcomes.
  • Clinical meaningfulness: at the pre-NDA meeting the FDA gave feedback on the clinical meaningfulness of the primary endpoint results and the limitations of the PROs, and indicated additional analyses and justification may be needed.
  • Sponsor: the prospectus describes LunAIRo as a trial the company initiated.

APC-APN-306

Objective
Location and study date
Registry dates and status, last updated May 2025
FieldRegistry entry
Study start (actual)“2024-07-03”
Primary completion (estimated)“2026-06-30”
Last update posted“2025-05-13”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
FieldRegistry entry
Enrollment (estimated)“1280”
Description of analysis sets

No evidence found.

Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • Design: open-label, single-group continuation study with no comparator; the registered primary outcomes are counts of participants with adverse events, vital sign abnormalities, and concomitant therapy.
  • Population: eligibility required completion of a parent phase 3 trial without permanent discontinuation of study drug, so participants who stopped study drug in the parent trials were not eligible.
  • Status: the registry record (last updated 2025-05-13) lists an estimated enrollment of 1,280 and an estimated primary completion of 2026-06-30, while the prospectus states the trial was completed in 2026.
  • Results: the only results are interim data from a 2025 congress abstract, with 102 participants enrolled (70% of eligible). The abstract states that data collected to date support long-term safety without reporting adverse event data, and no baseline, efficacy, patient-reported outcome, or analysis-set information is available.
  • Exploratory ring oximetry and mobile-application PROs were optional; 73 participants (72%) opted in.
  • Sponsor: the prospectus states that Syneos provided services to the company in connection with the trial.

MARIPOSA

Objective
Location and study date
Registry dates
FieldRegistry entry
Study start (actual)“2021-11-29”
Primary completion (actual)“2022-07-20”
Study completion (actual)“2022-08-03”
Study design
Eligibility criteria
Inclusion and exclusion criteria in the publication (AHI4 of 10 to 45 by two polysomnograms)

“Participants were adults with OSA with a mean apnea–hypopnea index using the ⩾4% desaturation criterion for hypopneas (AHI4) of 10–45 based on two screening/baseline polysomnography (PSG) studies, with <25% of events comprising central or mixed apnea.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Age requirement was 18–65 years for men and 18–75 for women. Body mass index was required to be ⩽38 kg/m2 for men and ⩽40 kg/m2 for women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Key exclusion criteria were clinically important sleep disorders other than OSA, active cardiac diseases (rhythm disturbance, coronary artery disease, or heart failure), hypertension requiring more than two drugs for control, craniofacial malformation or grade ⩾3 tonsillar hypertrophy, work schedule involving night or shift work, and chronic therapy with monoamine oxidase inhibitors, norepinephrine reuptake inhibitors, α-1 antagonists, tricyclic antidepressants, strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, duloxetine), opioids, muscle relaxants, wake-promoting agents, antipsychotic agents, anticholinergic agents, or warfarin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants treated with CPAP, oral or nasal devices, or positional devices could enroll as long as the devices had not been used for ⩾2 weeks before the first PSG study and were not used during participation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Treatment
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registry enrollment of 294 participants, including the AD504 arms
Description of analysis sets
Results
Participant disposition
Registry participant flow, all arms including AD504
MilestoneAD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlacebo
Started“41”“42”“43”“40”“64”“64”
Completed“35”“33”“38”“38”“49”“59”
Not completed“6”“9”“5”“2”“15”“5”
Withdrawn due to adverse event“5”“5”“3”“1”“12”“1”
Baseline characteristics
Demographic and clinical characteristics of the safety population
CharacteristicPlacebo (n = 63)Atomoxetine 75 mg (n = 63)AD109 2.5/75 mg (n = 42)AD109 5/75 mg (n = 41)
Age, years, median (IQR)“57 (48–62)”View highlighted excerpt for this quote“56 (49–60)”View highlighted excerpt for this quote“53.5 (44–58)”View highlighted excerpt for this quote“55 (49–60)”View highlighted excerpt for this quote
Female sex“27 (42.9%)”View highlighted excerpt for this quote“22 (34.9%)”View highlighted excerpt for this quote“17 (40.5%)”View highlighted excerpt for this quote“19 (46.3%)”View highlighted excerpt for this quote
BMI, kg/m2, median (IQR)“32.0 (27.2–35.2)”View highlighted excerpt for this quote“31.2 (28.11–34.6)”View highlighted excerpt for this quote“34.5 (31.6–36.6)”View highlighted excerpt for this quote“31.2 (27.5–34.0)”View highlighted excerpt for this quote
CPAP use“29 (46.1%)”View highlighted excerpt for this quote“30 (47.6%)”View highlighted excerpt for this quote“18 (42.9%)”View highlighted excerpt for this quote“21 (50.2%)”View highlighted excerpt for this quote
Black or African American“9 (14.3%)”View highlighted excerpt for this quote“5 (7.9%)”View highlighted excerpt for this quote“11 (26.2%)”View highlighted excerpt for this quote“6 (14.6%)”View highlighted excerpt for this quote
White“48 (76.2%)”View highlighted excerpt for this quote“52 (82.5%)”View highlighted excerpt for this quote“28 (66.7%)”View highlighted excerpt for this quote“33 (80.5%)”View highlighted excerpt for this quote
Hypertension“14 (22%)”View highlighted excerpt for this quote“8 (13%)”View highlighted excerpt for this quote“6 (14%)”View highlighted excerpt for this quote“12 (29%)”View highlighted excerpt for this quote
Diabetes“1 (2%)”View highlighted excerpt for this quote“8 (13%)”View highlighted excerpt for this quote“3 (7%)”View highlighted excerpt for this quote“4 (10%)”View highlighted excerpt for this quote
Registry baseline age and body mass index, safety set of all arms
CharacteristicAD109 75/5mgAD109 75/2.5mgAtomoxetine 75mgPlaceboTotal (all six arms)
Participants“41”“42”“63”“63”“292”
Age, years, mean (SD)“54.2(9.24)”“51.5(9.22)”“52.8(10.95)”“54.9(9.03)”“54.2(9.49)”
BMI, kg/m2, mean (SD)“31.12(4.085)”“33.43(4.352)”“31.16(4.716)”“31.17(4.719)”“31.65(4.389)”
Efficacy results
Respiratory parameters: AHI4 (4% criterion) in NREM and REM sleep
ArmNREM baselineNREM treatmentNREM placebo-adjusted changeREM baselineREM treatmentREM placebo-adjusted change
Placebo“19.3 (9.4–27.7)”View highlighted excerpt for this quote“16.7 (9.2–27.3)”View highlighted excerpt for this quoteNot applicable“20.9 (9.3–33.9)”View highlighted excerpt for this quote“20.3 (6.1–36.1)”View highlighted excerpt for this quoteNot applicable
Atomoxetine 75 mg“18.4 (9.4–28.6)”View highlighted excerpt for this quote“11.4 (4.4–19.4)”View highlighted excerpt for this quote“−4.22 (−7.81 to −0.63)”View highlighted excerpt for this quote“28.1 (15.7–21.6)”View highlighted excerpt for this quote“18.5 (9.1–26.8)”View highlighted excerpt for this quote“−5.77 (−11.66 to 0.71)”View highlighted excerpt for this quote
AD109 2.5/75 mg“16.0 (9.6–24.7)”View highlighted excerpt for this quote“10.1 (3.5–16.4)”View highlighted excerpt for this quote“−5.38 (−9.41 to −1.34)”View highlighted excerpt for this quote“30.2 (18.1–50.7)”View highlighted excerpt for this quote“18.2 (7.6–43.5)”View highlighted excerpt for this quote“−5.67 (−12.74 to 1.41)”View highlighted excerpt for this quote
AD109 5/75 mg“19.0 (10.1–30.7)”View highlighted excerpt for this quote“8.3 (5.9–19.5)”View highlighted excerpt for this quote“−6.45 (−10.44 to −2.46)”View highlighted excerpt for this quote“22.6 (13.0–34.4)”View highlighted excerpt for this quote“13.8 (6.6–31.8)”View highlighted excerpt for this quote“−3.34 (−10.39 to 3.72)”View highlighted excerpt for this quote
Registry primary outcome: change in AHI4 (4% criterion), combined AD109 arms, mITT
GroupParticipants analyzedLS mean change from baseline (95% CI), events/hr
AD109 combined dose arms“69”“-7.38 (-9.53 to -5.23)”
AD109 75/5mg“35”“-7.40 (-10.41 to -4.38)”
AD109 75/2.5mg“34”“-7.37 (-10.44 to -4.30)”
Placebo“62”“-0.21 (-2.49 to 2.07)”
Sleep architecture: total sleep time, REM sleep, and wake after sleep onset
Parameter and armBaseline, median (IQR)Treatment, median (IQR)Placebo-adjusted change, LS mean (95% CI)
TST, min: placebo“386.4 (362.3–428.0)”View highlighted excerpt for this quote“399.4 (358.5–426.5)”View highlighted excerpt for this quoteNot applicable
TST, min: atomoxetine 75 mg“396.4 (364.0–427.0)”View highlighted excerpt for this quote“372.2 (340.5–406.0)”View highlighted excerpt for this quote“−21.46 (−34.3 to −8.59)”View highlighted excerpt for this quote
TST, min: AD109 2.5/75 mg“387.5 (352.8–412.9)”View highlighted excerpt for this quote“385.5 (364.8–416.5)”View highlighted excerpt for this quote“2.48 (−12.01 to 16.96)”View highlighted excerpt for this quote
TST, min: AD109 5/75 mg“387.9 (360.9–425.8)”View highlighted excerpt for this quote“392.6 (355.5–421.8)”View highlighted excerpt for this quote“−5.37 (−19.65 to 8.91)”View highlighted excerpt for this quote
REM sleep, %TST: placebo“17.9 (14.7–20.1)”View highlighted excerpt for this quote“17.2 (13.6–20.8)”View highlighted excerpt for this quoteNot applicable
REM sleep, %TST: atomoxetine 75 mg“17.8 (13.7–19.0)”View highlighted excerpt for this quote“6.8 (3.5–11.3)”View highlighted excerpt for this quote“−9.32 (−11.14 to −7.50)”View highlighted excerpt for this quote
REM sleep, %TST: AD109 2.5/75 mg“18.6 (14.3–23.0)”View highlighted excerpt for this quote“7.5 (3.7–12.7)”View highlighted excerpt for this quote“−9.74 (−11.78 to −7.69)”View highlighted excerpt for this quote
REM sleep, %TST: AD109 5/75 mg“17.3 (13.5–20.1)”View highlighted excerpt for this quote“5.6 (2.5–10.2)”View highlighted excerpt for this quote“−10.79 (−12.79 to −8.78)”View highlighted excerpt for this quote
WASO, min: placebo“65.1 (41.5–97.8)”View highlighted excerpt for this quote“58.9 (44.5–101.8)”View highlighted excerpt for this quoteNot applicable
WASO, min: atomoxetine 75 mg“70.1 (44.3–98.8)”View highlighted excerpt for this quote“92.9 (61–124.3)”View highlighted excerpt for this quote“20.32 (8.07 to 32.58)”View highlighted excerpt for this quote
WASO, min: AD109 2.5/75 mg“75.6 (56.8–104.3)”View highlighted excerpt for this quote“78.9 (56.8–98.3)”View highlighted excerpt for this quote“0.11 (−13.69 to 13.91)”View highlighted excerpt for this quote
WASO, min: AD109 5/75 mg“73.3 (43.3–93.5)”View highlighted excerpt for this quote“77.0 (48.3–106.3)”View highlighted excerpt for this quote“8.21 (−5.37 to 21.79)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Patient-reported outcomes, placebo-adjusted change from baseline
OutcomeAtomoxetine 75 mgAD109 2.5/75 mgAD109 5/75 mg
PROMIS fatigue, adjusted T-score“−0.07 (−2.93 to 2.79)”View highlighted excerpt for this quote“−3.56 (−6.77 to −0.35)”View highlighted excerpt for this quote“0.10 (−3.02 to 3.21)”View highlighted excerpt for this quote
PROMIS sleep impairment, adjusted T-score“−0.02 (−3.28 to 3.24)”View highlighted excerpt for this quote“−1.99 (−5.67 to 1.69)”View highlighted excerpt for this quote“−0.35 (−3.91 to 3.21)”View highlighted excerpt for this quote
PROMIS sleep disturbance, adjusted T-score“2.40 (−0.07 to 4.87)”View highlighted excerpt for this quote“1.12 (−1.66 to 3.89)”View highlighted excerpt for this quote“0.21 (−2.48 to 2.90)”View highlighted excerpt for this quote
Modified short SAQLI“0.54 (−4.29 to 5.37)”View highlighted excerpt for this quote“−2.28 (−7.73 to 3.17)”View highlighted excerpt for this quote“2.02 (−3.25 to 7.29)”View highlighted excerpt for this quote
ESS score“0.30 (−1.15 to 1.74)”View highlighted excerpt for this quote“−0.23 (−1.85 to 1.39)”View highlighted excerpt for this quote“0.64 (−0.94 to 2.22)”View highlighted excerpt for this quote
PGI-S“−0.25 (−0.73 to 0.23)”View highlighted excerpt for this quote“−0.16 (−0.72 to 0.41)”View highlighted excerpt for this quote“−0.19 (−0.74 to 0.36)”View highlighted excerpt for this quote
QQ“0.44 (−1.2 to 2.12)”View highlighted excerpt for this quote“−0.26 (−2.14 to 1.63)”View highlighted excerpt for this quote“−1.01 (−2.85 to 0.83)”View highlighted excerpt for this quote
Safety results
Most common adverse events (at least three participants in any group)
Adverse eventPlacebo (n = 63)Atomoxetine 75 mg (n = 63)AD109 2.5/75 mg (n = 42)AD109 5/75 mg (n = 41)
Any adverse event“25 (39.7%)”View highlighted excerpt for this quote“51 (81%)”View highlighted excerpt for this quote“26 (61.9%)”View highlighted excerpt for this quote“32 (78%)”View highlighted excerpt for this quote
Adverse event leading to discontinuation“1 (2%)”View highlighted excerpt for this quote“12 (19%)”View highlighted excerpt for this quote“5 (12%)”View highlighted excerpt for this quote“5 (12%)”View highlighted excerpt for this quote
Dry mouth“3 (5%)”View highlighted excerpt for this quote“17 (27%)”View highlighted excerpt for this quote“10 (24%)”View highlighted excerpt for this quote“24 (59%)”View highlighted excerpt for this quote
Insomnia“2 (3%)”View highlighted excerpt for this quote“23 (37%)”View highlighted excerpt for this quote“11 (26%)”View highlighted excerpt for this quote“9 (22%)”View highlighted excerpt for this quote
Urinary hesitation/flow decrease“0”View highlighted excerpt for this quote“14 (22%)”View highlighted excerpt for this quote“3 (7%)”View highlighted excerpt for this quote“9 (22%)”View highlighted excerpt for this quote
Constipation“2 (3%)”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“5 (12%)”View highlighted excerpt for this quote
Nausea“2 (3%)”View highlighted excerpt for this quote“4 (6%)”View highlighted excerpt for this quote“5 (12%)”View highlighted excerpt for this quote“4 (10%)”View highlighted excerpt for this quote
Decreased appetite“1 (2%)”View highlighted excerpt for this quote“5 (8%)”View highlighted excerpt for this quote“2 (5%)”View highlighted excerpt for this quote“4 (10%)”View highlighted excerpt for this quote
Feeling jittery“1 (2%)”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2 (5%)”View highlighted excerpt for this quote“3 (7%)”View highlighted excerpt for this quote
Somnolence“1 (2%)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (2%)”View highlighted excerpt for this quote“3 (7%)”View highlighted excerpt for this quote
Heart rate and blood pressure versus placebo
Registry serious adverse events
MeasureAD109 75/5mgAD109 75/2.5mgAtomoxetine 75mgPlacebo
Serious adverse events“0/41 (0.00%)”“0/42 (0.00%)”“0/63 (0.00%)”“0/63 (0.00%)”
Study limitations
Summary
  • Design: phase 2 dose-finding trial with 4 weeks of dosing; the authors describe its exploratory nature, and no adjustment for multiple comparisons was made.
  • Population: AHI4 of 10 to 45 on two baseline polysomnograms, ages 18 to 65 (men) or 18 to 75 (women), and BMI up to 38 (men) or 40 (women) kg/m2. Exclusions included other clinically important sleep disorders (the prospectus names a history of insomnia), active cardiac disease, and hypertension requiring more than two drugs. PAP intolerance was not required; prior device users enrolled after 2 weeks without use, and 42.9% to 50.2% of each arm reported CPAP use.
  • Eligibility scoring: eligibility used site scoring, and endpoints used central scoring, which led to inclusion of 29 participants with baseline AHI4 below 10 after central scoring.
  • Primary endpoint differs by source: the publication tests each AD109 dose against placebo, and the registry names the combined AD109 arms against placebo. The registry states the trial was not powered to compare individual doses and that individual dose results should be interpreted descriptively.
  • Missing data: the statistical analysis plan had no prespecified imputation, so efficacy used the modified intention-to-treat population (181 of 211 randomized); the intention-to-treat analysis was post hoc.
  • Discontinuation: study discontinuation due to adverse events was 5 (12%) in each AD109 group, 12 (19%) with atomoxetine alone, and 1 (2%) with placebo.
  • Outcomes: the authors attribute the lack of PRO differences to a placebo effect and mild baseline symptoms, PROs were analyzed in the subset with assessments, and the authors suggest limited REM data during treatment as a possible reason the REM reduction was not significant versus placebo.
  • Reporting: registry enrollment of 294 includes two AD504 arms reported separately, and registry results were first posted on 2026-08-12, after study completion on 2022-08-03.
  • Source discrepancies: the publication states no serious adverse events were reported and also that two events classified as serious led to discontinuation with atomoxetine alone, while the registry lists 0 serious adverse events in every arm. Dry mouth with placebo is 3 (5%) in the publication and 10/63 (15.87%) in the registry. The prospectus gives a start in December 2021, and the registry and publication give November 29, 2021.
  • Sponsor: the prospectus describes MARIPOSA as a trial the company initiated.

APC-APN-201

Objective
Location and study date
Study design
Registered design details
Eligibility criteria
Treatment
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • Design: open-label, 6-week phase 2 study with no placebo arm; the arms differ only in concomitant GLP-1 receptor agonist use, while the registry lists the allocation as randomized.
  • Size: 40 participants at 4 U.S. sites, with 22 receiving AD109 alone and 18 receiving AD109 with a GLP-1 receptor agonist, against about 20 planned per arm.
  • Population: ages 18 to 75, BMI 27 to 43 (men) or 45 (women) kg/m2, and REI4 above 5 and below 45 on home sleep apnea testing. Exclusions included bothersome insomnia or bladder outlet obstruction, narrow angle glaucoma, and prior gastric weight loss surgery. Prior device users enrolled after 2 weeks without use.
  • Endpoints: the primary outcome was spontaneously reported adverse events. Efficacy was the proportion with at least 50% REI4 reduction on home sleep apnea testing at week 5, reported as 33.3% and 29.4%.
  • Reporting: results are available only from a congress abstract, without baseline characteristics or PROs.
  • Sponsor: the abstract states the study was supported by Apnimed.

APC-004

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using hypoxic burden as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed for the primary outcome in the registry
FieldQuoted record
Enrollment (actual)“Enrollment (Actual) 32”
Participants analyzed for the primary outcome, each comparison“Overall Number of Participants Analyzed 27 27 27”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Respiratory polysomnography parameters by treatment, median (interquartile range), AHI and ODI with 4% desaturation criterion
Registry primary outcome: mean difference in hypoxic burden (95% confidence interval), events with 4% or greater desaturation
ComparisonLog10 HB, difference in log10HB[(%*min)/h]Raw HB, (%*min)/h
AD109 dose 1 (atomoxetine 75 mg) vs placebo“-0.40 (-0.54 to -0.25)”“-6.90 (-10.20 to -3.60)”
AD109 dose 2 (atomoxetine 37.5 mg) vs placebo“-0.21 (-0.36 to -0.07)”“-4.70 (-8.01 to -1.38)”
Dose 2 vs dose 1“0.18 (0.04 to 0.33)”“2.20 (-1.23 to 5.36)”
Health-related quality of life and patient-reported outcomes
Safety results
Registry adverse events: deaths, serious adverse events, and other adverse events at a 5% threshold
Sleep and morning vital signs by treatment, median (interquartile range)
Study limitations
Summary
  • Design: single-dose crossover with one night of polysomnography per treatment, separated by washouts of at least 1 week.
  • Population: AHI4 of 5 to 20 events/h, ages 25 to 65, and BMI 18.5 to 40.0 kg/m2, with exclusion of other active sleep disorders, medications affecting respiratory, muscle, or neurologic function, and unstable medical disorders (the prospectus names a history of insomnia). The registry describes the population as mild obstructive sleep apnea, and the publication as mild or low-moderate OSA.
  • Size: 32 participants were randomized, 31 were treated, and 27 were analyzed for each primary comparison in the registry.
  • Hypoxic burden definition differs by source: the publication includes each apnea or hypopnea regardless of associated desaturation, and the registry includes events with 4% or greater desaturation. An accompanying editorial states that further validation of the measure is needed.
  • REM analysis: only 13 participants had REM sleep on both placebo and high-dose AD109, which the authors state left the REM analysis without statistical power.
  • Funding: the publication states the study was funded by Apnimed.

APC-003

Objective
Location and study date
Registered study dates
FieldQuoted record
Study start (actual)“2020-10-27”
Primary completion (actual)“2021-05-28”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using hypoxic burden as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled and analyzed participants in the registry
Description of analysis sets
Results
Participant disposition
Participants starting and completing each period, with reasons for not completing
Baseline characteristics
Efficacy results
Registry primary outcome: least squares mean change in log10 hypoxic burden (95% confidence interval), events with 4% or greater desaturation, mITT
TreatmentLog10HB4%[%min/hour]
AD109 (n = 59)“-0.41 (-0.54 to -0.28)”
Atomoxetine (n = 59)“-0.36 (-0.49 to -0.23)”
R-oxybutynin (n = 59)“-0.04 (-0.17 to 0.09)”
Placebo (n = 59)“-0.06 (-0.18 to 0.07)”
Health-related quality of life and patient-reported outcomes
Safety results
Registry adverse events: deaths, serious adverse events, and other adverse events at a 3% threshold
EventA: AD109B: Atomoxetine 75 mg + placeboC: R-oxybutynin 2.5 mg + placeboD: Placebo + placebo
All-cause mortality“0/56 (0.00%)”“0/54 (0.00%)”“0/54 (0.00%)”“0/57 (0.00%)”
Serious adverse events, total“1/56 (1.79%)”“0/54 (0.00%)”“0/54 (0.00%)”“0/57 (0.00%)”
Atrial fibrillation (serious)“1/56 (1.79%)”“0/54 (0.00%)”“0/54 (0.00%)”“0/57 (0.00%)”
Seizure (serious)“1/56 (1.79%)”“0/54 (0.00%)”“0/54 (0.00%)”“0/57 (0.00%)”
Gastroesophageal reflux disease“2/56 (3.57%)”“2/54 (3.70%)”“0/54 (0.00%)”“0/57 (0.00%)”
Study limitations
Summary
  • Publication status: results are available only from the registry record and the company prospectus.
  • Design: four-period single-dose crossover with one-week washouts; participants who withdrew were not replaced, and 49 participants started the fourth period. The registry states the analysis did not analyze data by period and reported adverse events by treatment group only.
  • Eligibility differs by source: the registry states AHI 10 to below 20, or 20 or more if other polysomnography criteria were met, while the prospectus states AHI 10 to 45 events/h with randomization limited to participants showing signs of low upper airway collapsibility. Ages were 25 to 65, and exclusions included a history of insomnia and clinically significant cardiac disease.
  • Open-label extension: 37 of 60 participants received AD109 for 4 weeks without a control group; the reported reductions in hypoxic burden and AHI at week 4 and the SAQLI change versus baseline come from the prospectus.
  • Withdrawals differ by source: the registry lists first-period non-completion as incorrectly randomized, lost to follow-up, and physician decision (1 each), while the prospectus states two participants withdrew because of adverse events (pleurisy and atrial fibrillation).
  • Safety: one serious adverse event (possible seizure versus arrhythmia or atrial fibrillation) occurred with AD109 in a participant with a previously undisclosed history of arrhythmia and was considered unrelated to the drug.
  • Sponsor: the prospectus describes APC-003 as a trial the company initiated.